Testing effectiveness (Phase 2)Active Not RecruitingNCT06400303
What this trial is testing
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Who this might be right for
Systemic SclerosisSystemic Sclerosis - Diffuse CutaneousSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Kyverna Therapeutics 3